The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study

doi:10.1177/17588359211018022

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24111

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24111

Title:	The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study
Authors:	Huang, YH;Hung, JY;Ko, HW;Su, PL;Lai, CL;Chang, HC;Hsia, TC;Lin, SH;Wu, KL;Yang, CT;Su, WC;Chu, YC;Wang, CC;Liao, WY;Lin, YT;Lin, CH;Lin, MC;Hsu, KH;Tseng, JS;Yang, TY;Chen, KC;Lee, MH;Yu, SL;Ho, CC;Chang, GC
Keywords:	epidermal growth factor receptor;local treatment;more than five years;non-small cell lung cancer;scoring model;tyrosine kinase inhibitor
Date:	2021
Issue Date:	2022-08-05T09:47:59Z (UTC)
Publisher:	SAGE PUBLICATIONS LTD
ISSN:	1758-8340
Abstract:	Background: The relative importance of predictive factors for advanced non-small cell lung cancer (NSCLC) patients on epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment remains unclear. Materials and methods: We retrospectively enrolled advanced NSCLC patients with single first-generation EGFR-TKI treatment for 5years (Y) in Taiwan. Clinical data was collected and compared with those of another cohort with single first-line EGFR-TKI treatment for <5Y. Plasma cell-free DNA (cfDNA) samples were collected from patient subsets, pre- and post-TKI, in the >5Y group. Results: Overall, 128 and 278 patients were enrolled in the 5Y and <5Y groups, respectively. Significant factors in the multivariate analysis of patients' characteristics including Eastern Cooperative Oncology Group performance status 0-1, postoperative recurrence, without brain metastasis, oligometastasis (each score of 2), female sex, erlotinib use, and without bone metastasis (each score of 1), were incorporated into a risk scoring system. The area under the receiver operating characteristic curve was 0.82 [95% confidence interval (CI): 0.78-0.86]. Of the plasma cfDNA samples from 33 patients in the 5Y group, only 1 had a T790M in 25 patients without progressive disease. In 27 patients with single agent use for 96months, 22 (81.5%) received local treatment (surgery or radiotherapy) for the primary lung tumor before and during TKI treatment. Conclusion: For NSCLC patients with single first-generation EGFR-TKI use for 5Y, factors with different relative importance exist and the risk-scoring model is feasible with modest accuracy. The role of local treatment for primary tumors in patients with long-term TKI use requires further investigation.
URI:	http://dx.doi.org/10.1177/17588359211018022 https://www.webofscience.com/wos/woscc/full-record/WOS:000697387700001 https://ir.csmu.edu.tw:8080/handle/310902500/24111
Relation:	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY ,2021,v13
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	246	View/Open

Loading...